检索范围:
排序: 展示方式:
《医学前沿(英文)》 2022年 第16卷 第1期 页码 139-149 doi: 10.1007/s11684-021-0835-8
关键词: B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20
《医学前沿(英文)》 doi: 10.1007/s11684-023-0996-8
Passive antibody therapy in emerging infectious diseases
《医学前沿(英文)》 doi: 10.1007/s11684-023-1021-y
关键词: SARS-CoV-2 COVID-19 convalescent plasma hyperimmunoglobulin neutralizing monoclonal antibodies
Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT
《化学科学与工程前沿(英文)》 2012年 第6卷 第2期 页码 216-223 doi: 10.1007/s11705-012-1289-y
关键词: recombinant protein polyclonal antibody label-free biosensor impedance white spot syndrome virus (WSSV)
Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12
Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang
《医学前沿(英文)》 2019年 第13卷 第1期 页码 83-93 doi: 10.1007/s11684-019-0682-z
Colorectal cancer (CRC) is a common malignant tumor in the digestive tract, and 30%–85% of CRCs express epidermal growth factor receptors (EGFRs). Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC have been demonstrated to cause an S492R mutation in EGFR. However, little is known about the biological function of S492R EGFR. Therefore, we attempted to elucidate its biological function in CRC cells and explore new treatment strategies for this mutant form. Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibody CH12, which specifically recognizes an EGFR tumor-specific epitope, can bind efficiently to S492R EGFR. Furthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent cellular cytotoxicity effect on CRC cells bearing S492R EGFR than mAb C225. mAb CH12 obviously suppressed the growth of CRC xenografts with S492R EGFR mutations in vivo. Thus, mAb CH12 may be a promising therapeutic agent in treating patients with CRC bearing an S492R EGFR mutation.
关键词: S492R EGFR ectodomain mutation colorectal cancer mAb CH12 immunnotherapy
Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA
《环境科学与工程前沿(英文)》 2011年 第5卷 第3期 页码 409-416 doi: 10.1007/s11783-011-0349-8
关键词: cadmium hapten monoclonal antibody enzyme-linked immunosorbent assay (ELISA)
null
《医学前沿(英文)》 2016年 第10卷 第2期 页码 204-211 doi: 10.1007/s11684-016-0443-1
CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate epitope (glycotope) functionally involved in blood spread and liver metastasis of cancer cells by mediating the adhesion of cancer cells to endothelial cells and hepatocytes, respectively. CD176 could be a promising target for antitumor immunotherapy. We applied B lymphocytes obtained from mice immunized with CD176 antigen and constructed a phage display library. A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from this library. The CD176 scFv was expressed in Escherichia coli and purified. The purified scFv can bind to the natural CD176 expressed on the surface of cancer cells. Furthermore, the CD176 scFv inhibits the adhesion of CD176+ cancer cells to endothelial cells and hepatocytes. This CD176 scFv provides a basis for future development of recombinant CD176-specific antibodies that can be used in therapeutic application.
关键词: CD176 Thomsen-Friedenreich antigen scFv cancer therapy adhesion metastasis
提升疗效的修饰型治疗性抗体国内外研究进展 Review
戴济民, 张雪芹, 戴竞耀, 杨向民, 陈志南
《工程(英文)》 2021年 第7卷 第11期 页码 1529-1540 doi: 10.1016/j.eng.2020.06.030
生物治疗药物市场的繁荣反映了治疗性抗体药物用于治疗癌症、炎性疾病和难治性感染的可行性和有效性。随着抗体药物临床试验和转化研究中出现的结合效率不高、效应功能降低和不良反应频发等问题的解决,治疗性抗体的修饰在抗体药物的研发进程中得到了前所未有的蓬勃发展。为了提升抗体的结合活性、循环中的半衰期、靶细胞的有效性,并最终实现改善抗体药物的疗效,抗体可主要通过以下途径修饰:①糖基化修饰;②抗体恒定区(Fc)改造;③抗体亚类重构;④构建抗体-药物偶联物(ADC);⑤基于单链可变区片段(scFv)的嵌合抗原受体T细胞(CAR-T);⑥双特异性抗体(bsAb)。过去几十年来全球在修饰型治疗性抗体的领域取得了许多成就,中国作为对于生物治疗药物需求巨大并且拥有巨大研发潜力的国家在该领域亦发挥了积极作用。本文概括了修饰型治疗性抗体在当前国际研究中取得的进展,并在单独的章节中重点介绍了中国在该领域取得的成果。
使用数据驱动模型优化抗体纯化策略 Article
刘松崧, Lazaros G. Papageorgiou
《工程(英文)》 2019年 第5卷 第6期 页码 1077-1092 doi: 10.1016/j.eng.2019.10.011
本工作致力于抗体片段纯化过程的多尺度优化。优化了生产过程中的色谱决策,包括色谱柱的数量及其大小,每批的循环数以及操作流速。使用基于微型实验数据的制造规模模拟数据集,建立了以负载质量、流速和柱床高度为输入的色谱通量数据驱动模型。与其他方法相比,分段线性回归建模方法具有简单、预测精度高的优点。提出了两种混合整数非线性规划(MINLP)模型,结合数据驱动模型,以最小化每克抗体纯化过程的总成本。然后,使用线性化技术和多参数分解将这些MINLP模型重新构造为混合整数线性规划(MILP)模型。研究了两个具有不同色谱柱尺寸替代品的工业相关案例,以证明所提出模型的适用性。
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie
《医学前沿(英文)》 2021年 第15卷 第4期 页码 644-648 doi: 10.1007/s11684-021-0847-4
关键词: neutralizing antibody antibody cocktail SARS-CoV-2 COVID-19 therapeutic strategy
一种通过计算机辅助抗体设计技术获得的靶向人表皮生长因子受体2的新型全人抗体HF Article
乔春霞, 吕明, 李新颖, 郞小玲, 吕守芹, 龙勉, 黎燕, 耿树生, 林周, 沈倍奋, 冯健男
《工程(英文)》 2021年 第7卷 第11期 页码 1566-1576 doi: 10.1016/j.eng.2020.10.024
全人抗体免疫原性小、安全性高。目前研究的处于临床试验阶段的大多数抗体药物都是人源化或全人抗体。全人抗体多通过噬菌体展示技术(体外)或转基因小鼠(体内)产生;其他方法包括B淋巴细胞永生化、人-人杂交瘤、单细胞聚合酶链反应等。本文描述了一种基于分子结构的计算机辅助设计新抗体技术,用于获得全人抗体。由于靶向人表皮生长因子受体2(HER2)的注射用曲妥珠单抗(赫赛汀)的结构复杂,我们首先针对赫赛汀识别HER2 的潜在表位设计了6 条短肽。随后,将这些肽作为抗体互补决定区,并采用适合的免疫球蛋白框架,获得名为“HF”的新型抗HER2 抗体。HF比赫赛汀具有更高的亲和力和更有效的抗肿瘤活性。我们的工作为用于机理研究以及免疫相关疾病(如癌症和传染病)的成像和临床应用的新型全人抗体的快速设计和筛选提供了有用工具。
From SARS to MERS: evidence and speculation
null
《医学前沿(英文)》 2016年 第10卷 第4期 页码 377-382 doi: 10.1007/s11684-016-0466-7
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic pathogen. In 2012, the infectious outbreak caused by MERS-CoV in Saudi Arabia has spread to more than 1600 patients in 26 countries, resulting in over 600 deaths. Without a travel history, few clinical and radiological features can reliably differentiate MERS from SARS. But in real world, comparing with SARS, MERS presents more vaguely defined epidemiology, more severe symptoms, and higher case fatality rate. In this review, we summarize the recent findings in the field of MERS-CoV, especially its molecular virology, interspecies mechanisms, clinical features, antiviral therapies, and the further investigation into this disease. As a newly emerging virus, many questions are not fully answered, including the exact mode of transmission chain, geographical distribution, and animal origins. Furthermore, a new protocol needs to be launched to rapidly evaluate the effects of unproven antiviral drugs and vaccine to fasten the clinical application of new drugs.
关键词: middle east respiratory syndrome animal origin cross-species transmission monoclonal antibody
Reduction of rough set attribute based on immune clone selection
LIANG Lin, XU Guang-hua
《机械工程前沿(英文)》 2006年 第1卷 第4期 页码 413-417 doi: 10.1007/s11465-006-0049-4
关键词: inherent distribution maturation evolution diversity antibody
靶向膜蛋白的抗体药物开发的新进展 Review
Georgina To’a Salazar, 黄子逸, 张凝艳, 张学光, 安志强
《工程(英文)》 2021年 第7卷 第11期 页码 1541-1551 doi: 10.1016/j.eng.2020.11.013
在疾病干预的众多膜蛋白靶标中,G蛋白偶联受体(GPCR)作为人体内最大的膜受体蛋白家族,成为很多药物的重要靶点,其次是离子通道、转运蛋白和激酶等。膜蛋白在细胞信号转导和运输中发挥了关键作用,当前药物研发面临的挑战在于进一步发掘此类膜蛋白的潜在靶点的干预价值,开发治疗性抗体药物。鉴于特异性抗体能够识别膜蛋白的灵敏特性,以及随着基因工程技术的进步,对已有抗体进行加工改造可获得适应多个靶点蛋白的特异性抗体。然而,成功分离特异靶向膜蛋白抗体取决于一系列因素。我们更易研制和识别结构简单且具有长片段胞外区的抗体分子,但对于高难度的靶点蛋白,如GPCR和其他复杂膜蛋白往往难以得到具有活性的候选抗体。目前若要开发针对复杂膜蛋白(如GPCR、离子通道、转运蛋白和激酶)的抗体药物,必须从抗原靶点设计、抗体筛选策略、先导抗体优化及药物研发模式方面进行考虑。深入研究靶标膜蛋白的结构有助于推进治疗性抗体药物的开发进程。本文概述了抗体靶向复杂膜蛋白的优势和挑战,以及膜蛋白抗原制备和抗体研发策略的最新进展。
Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic
《医学前沿(英文)》 2022年 第16卷 第6期 页码 984-990 doi: 10.1007/s11684-022-0930-5
关键词: influenza virus seroprevalence antibody COVID-19 cross-sectional study
标题 作者 时间 类型 操作
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific
期刊论文
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation
期刊论文
Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv
Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT
期刊论文
Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12
Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang
期刊论文
Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples
Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA
期刊论文
CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells
null
期刊论文
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie
期刊论文